Literature DB >> 32880827

Influence of smoking and obesity on treatment response in patients with axial spondyloarthritis: a systematic literature review.

Pablo Antonio Zurita Prada1, C L Urrego Laurín2, C A Guillén Astete2, S Kanaffo Caltelblanco2, V Navarro-Compán3.   

Abstract

To assess whether smoking and obesity are predictors of poor treatment response in patients with axial spondyloarthritis (axSpA). A systematic literature review was performed by searching in MEDLINE and EMBASE up to June 2019 with a strategy based on the PICO approach: Population: patients with axSpA; Intervention or exposure: smoking or obesity; Comparison: non-smokers (for smoking) and normal-weight individuals (for obesity); and Outcome: any response criteria currently validated for axSpA. The 2009 Oxford Centre for Evidence-based Medicine levels were used for assessing the studies quality. Out of 1873 references retrieved, 46 studies were selected for full-text review and 12 for data extraction: six stratified patients by smoking and six by obesity. All were longitudinal observational studies, except one, which was cross-sectional. Overall, these studies included 5291 patients (3917 for smoking and 1333 for obesity), and all these patients were on anti-tumor necrosis factor (anti-TNF) therapy. The quality of evidence was graded as level 2b except that from the cross-sectional study which was graded level 4. For smoking, the evidence found is inconsistent: two studies finding negative effects in response to anti-TNF while the other four found no differences in clinical response to this therapy. Regarding obesity, the evidence is more consistent: five of the six studies describing a negative influence in response to anti-TNF. According to the scientific evidence in patients with axSpA, obesity is associated with a more unsatisfactory response to anti-TNF therapy. A poorer response in smokers has yet to be demonstrated. Key Points • Identifying predictors of treatment response in axSpA, especially those that are modifiable, is relevant. • Obesity increases the risk of poorer response to anti-TNF agents in patients with axSpA. • Scientific evidence for smoking habit as a predictor of treatment response in axSpA is inconclusive.

Entities:  

Keywords:  Ankylosing spondylitis; Axial spondyloarthritis; Body mass index; Clinical response; Efficacy; Obesity; Outcome; Overweight; Predictors; Tobacco

Mesh:

Substances:

Year:  2020        PMID: 32880827     DOI: 10.1007/s10067-020-05319-6

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  1 in total

1.  Obesity decreases clinical efficacy and levels of adalimumab in patients with ankylosing spondylitis.

Authors:  José Rosas; Francisca Llinares-Tello; José Miguel Senabre-Gallego; Xavier Barber-Vallés; Gregorio Santos-Soler; Esteban Salas-Heredia; Ana Pons Bas; Catalina Cano Pérez; Mario García-Carrasco
Journal:  Clin Exp Rheumatol       Date:  2016-11-13       Impact factor: 4.473

  1 in total
  2 in total

1.  VEGF Profile in Early Undifferentiated Arthritis Cohort.

Authors:  Regina Sakalyte; Loreta Bagdonaite; Sigita Stropuviene; Sarune Naktinyte; Algirdas Venalis
Journal:  Medicina (Kaunas)       Date:  2022-06-20       Impact factor: 2.948

2.  Underweight and obesity are strong predictors of clinical outcomes in patients with ankylosing spondylitis: data from the Smart-phone SpondyloArthritis Management System.

Authors:  Lidong Hu; Xiaojian Ji; Yiwen Wang; Siliang Man; Xingkang Liu; Lei Wang; Jian Zhu; Jidong Cheng; Feng Huang
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-07-13       Impact factor: 5.346

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.